论文部分内容阅读
由于免疫学的发展,测定恶性肿瘤病人血清中的癌胚抗原(CEA)、甲胎蛋白(AFP)、免疫抑制物(IS)和免疫抑制酸性蛋白(IAP),可以早期诊断肿瘤和估价临床过程及预后。在头颈癌中,这方面的资料很少。作者应用单向扩散放免技术,测定了108例头颈鳞癌病人血清中的IS、IAP治疗前后的值。其中喉癌53例,上颌窦癌37例,鼻咽癌7例,下咽癌9例。还检查19个正常人作对照,对照组的平均值为:IS614±149μg/ml、IAP401±78μg/ml,以IS>912μg/ml、IAP>658μg/ml为异常。肿瘤病人各平均值如下:喉癌955±447μg
Due to the development of immunology, the determination of carcinoembryonic antigen (CEA), AFP, IS, and IAP in the serum of patients with malignant tumors can early diagnose the tumor and evaluate the clinical course And prognosis. In head and neck cancer, there is very little information on this. The authors applied one-way diffusion-free radioimmunoassay to determine the serum levels of IS and IAP in 108 patients with head and neck squamous cell carcinoma before and after treatment. Including laryngeal cancer in 53 cases, 37 cases of maxillary sinus cancer, nasopharyngeal carcinoma in 7 cases, 9 cases of hypopharyngeal carcinoma. Nineteen normal controls were also examined as controls, with mean IS614 ± 149 μg / ml and IAP401 ± 78 μg / ml, with IS> 912 μg / ml and IAP> 658 μg / ml as an abnormality. The average tumor patients are as follows: laryngeal cancer 955 ± 447μg